NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that John Cooke, MD, PhD has accepted an appointment to the Company’s Scientific Advisory Board to assist Pluristem with its efforts to further develop the Company’s product candidates and give patients a better chance.
